AssetMark Inc
PHIO icon

AssetMark Inc’s Phio Pharmaceuticals PHIO Stock Holding History

AssetMark Inc’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$134 Hold
110
– – ﹤0.01% 3362
2025
Q4 		$116 Hold
110
– – ﹤0.01% 3297
2025
Q3 		$273 Hold
110
– – ﹤0.01% 3016
2025
Q2 		$259 Hold
110
– – ﹤0.01% 2843
2025
Q1 		$143 Buy
+110
New +$203 ﹤0.01% 2548

Other funds holding PHIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

AssetMark Inc's PHIO Position: Q1 2026 in Review

AssetMark Inc held its Phio Pharmaceuticals (PHIO) position steady in Q1 2026 at 110 shares worth $134. The position accounts for ﹤0.01% of the portfolio, ranked #3362.

AssetMark Inc first reported a position in PHIO in Q1 2025 and has held it in 5 quarters since. The position peaked at $273 in Q3 2025. 24 funds tracked by Wall St. Rank hold PHIO as of Q1 2026.

  • AssetMark Inc held 110 shares of Phio Pharmaceuticals worth $134 as of Q1 2026.
  • AssetMark Inc left its Phio Pharmaceuticals share count unchanged in Q1 2026.
  • Phio Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #3362 holding.
  • AssetMark Inc first reported a position in Phio Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • AssetMark Inc's Phio Pharmaceuticals position peaked at $273 in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.